Chandra Vargeese

3.7k total citations · 1 hit paper
29 papers, 2.6k citations indexed

About

Chandra Vargeese is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Chandra Vargeese has authored 29 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 5 papers in Organic Chemistry and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Chandra Vargeese's work include Advanced biosensing and bioanalysis techniques (10 papers), RNA Interference and Gene Delivery (8 papers) and DNA and Nucleic Acid Chemistry (6 papers). Chandra Vargeese is often cited by papers focused on Advanced biosensing and bioanalysis techniques (10 papers), RNA Interference and Gene Delivery (8 papers) and DNA and Nucleic Acid Chemistry (6 papers). Chandra Vargeese collaborates with scholars based in United States, United Kingdom and Switzerland. Chandra Vargeese's co-authors include Shawn Zinnen, Keith Bowman, Barry Polisky, Dylan Morrissey, Jennifer A. Lockridge, Karin S. Blanchard, Kristi Jensen, Lloyd B. Jeffs, Narendra K. Vaish and Susan F. Radka and has published in prestigious journals such as Nucleic Acids Research, Nature Biotechnology and Hepatology.

In The Last Decade

Chandra Vargeese

29 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

2005 908 citations Dylan Morrissey, Jennifer A. Lockridge et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chandra Vargeese United States	17	2.2k	468	282	246	179	29	2.6k
Philipp Hadwiger Germany	22	2.2k 1.0×	619 1.3×	307 1.1×	292 1.2×	237 1.3×	40	2.8k
Vasant Jadhav United States	20	2.2k 1.0×	575 1.2×	287 1.0×	249 1.0×	150 0.8×	35	2.5k
Klaus Charissé United States	30	3.4k 1.5×	606 1.3×	233 0.8×	242 1.0×	87 0.5×	56	3.9k
Regina Heidenreich Germany	26	1.7k 0.8×	516 1.1×	315 1.1×	956 3.9×	155 0.9×	44	2.7k
Thazha P. Prakash United States	46	5.4k 2.4×	748 1.6×	330 1.2×	148 0.6×	245 1.4×	114	6.0k
Rudolph L. Juliano United States	30	2.4k 1.1×	264 0.6×	221 0.8×	151 0.6×	56 0.3×	56	2.9k
Walt F. Lima United States	30	3.1k 1.4×	431 0.9×	236 0.8×	105 0.4×	115 0.6×	42	3.4k
Elizaveta S. Leshchiner United States	11	1.4k 0.7×	561 1.2×	153 0.5×	206 0.8×	95 0.5×	13	1.9k
Amin Hajitou United Kingdom	29	1.7k 0.8×	569 1.2×	531 1.9×	261 1.1×	182 1.0×	64	3.0k
Birgit Schäfer Germany	21	1.5k 0.7×	230 0.5×	181 0.6×	145 0.6×	110 0.6×	33	2.1k

Countries citing papers authored by Chandra Vargeese

Since Specialization

Citations

This map shows the geographic impact of Chandra Vargeese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chandra Vargeese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chandra Vargeese more than expected).

Fields of papers citing papers by Chandra Vargeese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chandra Vargeese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chandra Vargeese. The network helps show where Chandra Vargeese may publish in the future.

Co-authorship network of co-authors of Chandra Vargeese

This figure shows the co-authorship network connecting the top 25 collaborators of Chandra Vargeese. A scholar is included among the top collaborators of Chandra Vargeese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chandra Vargeese. Chandra Vargeese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Yuanjing, Amy Andreucci, Naoki Iwamoto, et al.. (2022). Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD. Molecular Therapy — Nucleic Acids. 28. 558–570. 36 indexed citations

Liu, Yuanjing, Amy Andreucci, Naoki Iwamoto, et al.. (2021). WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (2302). Neurology. 96(15_supplement). 5 indexed citations

Byrne, Michael, Vinod Vathipadiekal, Luciano H. Apponi, et al.. (2021). Stereochemistry Enhances Potency, Efficacy, and Durability of Malat1 Antisense Oligonucleotides In Vitro and In Vivo in Multiple Species. Translational Vision Science & Technology. 10(1). 23–23. 19 indexed citations

Svrzikapa, Nenad, Kenneth Longo, Nripesh Prasad, et al.. (2020). Investigational Assay for Haplotype Phasing of the Huntingtin Gene. Molecular Therapy — Methods & Clinical Development. 19. 162–173. 12 indexed citations

Dale, Elena, Maria Frank-Kamenetsky, Yuanjing Liu, et al.. (2020). Stereopure Oligonucleotides for the Selective Silencing of Mutant Huntingtin (4703). Neurology. 94(15_supplement). 4 indexed citations

Iwamoto, Naoki, David C. Butler, Nenad Svrzikapa, et al.. (2017). Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nature Biotechnology. 35(9). 845–851. 263 indexed citations

Panzara, Michael, Carlo Rinaldi, Graham McClorey, et al.. (2017). Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD). Journal of the Neurological Sciences. 381. 277–278. 1 indexed citations

Wood, Matthew J. A., Keith Bowman, David Butler, et al.. (2017). WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration. Neuromuscular Disorders. 27. S217–S217. 4 indexed citations

Faller, Thomas, Esther van de Kerkhof, François Natt, et al.. (2014). Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice. Drug Metabolism and Disposition. 42(3). 431–440. 43 indexed citations

10.

Saberi, Maziyar, Simon Schenk, Takeshi Imamura, et al.. (2009). Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 297(5). E1137–E1146. 62 indexed citations

11.

Shen, Jikui, Hideo Akiyama, Yoshitsugu Saishin, et al.. (2005). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Therapy. 13(3). 225–234. 236 indexed citations

12.

Morrissey, Dylan, Jennifer A. Lockridge, Karin S. Blanchard, et al.. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology. 23(8). 1002–1007. 908 indexed citations breakdown →

13.

Morrissey, Dylan, Karin S. Blanchard, Kristi Jensen, et al.. (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†. Hepatology. 41(6). 1349–1356. 219 indexed citations

14.

Morrissey, Dylan, David A. Johnson, James A. McSwiggen, et al.. (2002). Characterization of nuclease‐resistant ribozymes directed against hepatitis B virus RNA*. Journal of Viral Hepatitis. 9(6). 411–418. 19 indexed citations

15.

Floege, Jürgen, Tammo Ostendorf, Ulf Janssen, et al.. (1999). Novel Approach to Specific Growth Factor Inhibition in Vivo. American Journal Of Pathology. 154(1). 169–179. 193 indexed citations

16.

Vargeese, Chandra. (1998). Efficient activation of nucleoside phosphoramidites with 4,5- dicyanoimidazole during oligonucleotide synthesis. Nucleic Acids Research. 26(4). 1046–1050. 107 indexed citations

17.

MCGEE, D. P. C., et al.. (1996). 2‘-Amino-2‘-deoxyuridine via an Intramolecular Cyclization of a Trichloroacetimidate. The Journal of Organic Chemistry. 61(2). 781–785. 64 indexed citations

18.

MCGEE, D. P. C., et al.. (1995). Efficient Synthesis of 2′-Amino-2′-deoxypyrimidine 5′-Triphosphates. Nucleosides and Nucleotides. 14(6). 1329–1339. 15 indexed citations

19.

Jellinek, Derek, et al.. (1995). Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor. Biochemistry. 34(36). 11363–11372. 171 indexed citations

20.

Vargeese, Chandra, et al.. (1994). Adenosine Deaminase Inhibitors. Synthesis and Biological Evaluation of Putative Metabolites of (+)-erythro-9-(2S-Hydroxy-3R-nonyl)adenine. Journal of Medicinal Chemistry. 37(22). 3844–3849. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact